Evidence map›Paper›PMID 42824750›Full record

ArticleGenetics in medicine open2026

Genome sequencing reveals the prevalence of Fabry disease-causing variants in Japan: Evidence from the Tohoku Medical Megabank.

Kai Susukita, Kotaro Nochioka, Masato Takase, Saori Yamamoto, Kazuki Kumada, Hideaki Suzuki, Kinuko Ohneda, Kenichi Noguchi, Yoko Izumi, Soichi Ogishima and 4 more

Abstract read
In one paragraph

Article in Genetics in medicine open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Kai SusukitaDepartment of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Kotaro NochiokaDepartment of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Masato TakaseTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Saori YamamotoDepartment of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Kazuki KumadaTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Hideaki SuzukiDepartment of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Kinuko OhnedaTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Kenichi NoguchiTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Yoko IzumiTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Soichi OgishimaTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Naoki NakayaTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Yoshikatsu EtoAdvanced Clinical Research Center and Asian LSD Center, Institute of Neurological disorders, Fukushima, Japan.
Atsushi HozawaTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Satoshi YasudaDepartment of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Fabry disease (FD) is an X-linked lysosomal storage disorder caused by deficient α-galactosidase A activity and characterized by multisystem involvement. Although considered rare, with reported prevalence ranging from 1 in 40,000 to 1 in 140,000, its true frequency in the general population remains uncertain. We aimed to determine the prevalence of FD-causing variants in a community-based cohort from the Tohoku Medical Megabank, Japan. Methods: Genome sequencing was performed in 68,615 individuals. Variant pathogenicity was classified according to American College of Medical Genetics and Genomics/Association for Molecular Pathology guidelines. Baseline demographics, serum α-galactosidase A (GLA) activity, plasma globotriaosylsphingosine, and self-reported health data were assessed. Results: Pathogenic GLA variants were identified in 4 individuals and a likely pathogenic variant in 1 individual (mean age 49.3 ± 15.9 years); all were female, corresponding to a prevalence of 1 in 13,723. All pathogenic variants were c.902G>A, associated with the cardiac phenotype, whereas the likely pathogenic variant was c.1076T>C. Mean plasma GLA activity was 5.64 ± 1.73 mmol/hr/mL in pathogenic variant carriers and 8.36 mmol/hr/mL in the likely pathogenic carrier. Plasma globotriaosylsphingosine levels were 3.7 ± 0.79 ng/mL and 0.96 ng/mL, respectively. Conclusion: Population based genome sequencing data suggest a higher prevalence of FD-causing variants in Japan than previously reported, highlighting potential underdiagnosis of late-onset FD in women.

Indexed as

Fabry diseaseGenome sequencingGlobotriaosylsphingosinePrevalence

Identifiers

PMID42824750
PMCPMC13627940

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.